Clinical trial · Observational
New MRI Biomarkers in Head and Neck Cancers
Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers
NCT03483337CI-TRIAL-00108204recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. The purpose of this study is to see if new MRI methods can give us more information about the tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI examinations | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- recurrent or metastatic head and neck cancer patients
- description
- Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
- interventionNames
- Other: MRI examinations
- label
- head and neck cancer or thyroid cancers (differentiated and undifferentiated)
- description
- All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies during week 2 of treatment. If patients receive 70Gy, they will also receive a scan during week 4 of treatment, if needed by treating physician. Scans will be performed to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed.
- interventionNames
- Other: MRI examinations
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region. * Group 2 patients: * Biopsy proven recurrent or metastatic or definitive head and neck cancer or (differentiated and undifferentiated) thyroid cancers in the head and neck region only. * Patients planning to undergo reatment at MSK Exclusion Criteria: * Patient would require anesthesia for the study * Patients who are claustrophobic * Patients selecting treatment outside of MSK * Known reaction to Gd based contrast agent * Patients who have presence of a known contradiction to MRI * Pacemaker * Aneurysm clips * Patients with implants that are contradicted for MR imaging will be excluded * Pregnant * Age and mental status wherein he /she is unable to cooperate for MRI study
References
Publications (0)
Data not yet available
No reference posted for this study.